Q702
MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 46 patients (estimated)
- Sponsors
- Mayo Clinic
- Tags
- AXL Inhibitor, CSF1R Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 2034
- NCT Identifier
- NCT06712810
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.